The FDA approved Glaukos's iDose TR (travoprost intracameral implant) for a single administration per eye. The 75 µg prostaglandin analog implant is indicated for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma.

According to the company, iDose TR is a first-of-its-kind, long-duration, intracameral procedural pharmaceutical therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost inside the eye for extended periods of time. The implant seeks to remove the treatment obstacles of patient adherence and chronic side effects associated with topical glaucoma medications. 

“With  ... iDose TR we now have a new tool that will confront the standard legacy practice of relying on topical drops, which are known to cause uncomfortable side effects and present a myriad of challenges such as treatment adherence, complex dosing regimens, and difficulty with self-administration,” John Berdahl, MD, clinician and researcher at Vance Thompson Vision, said in a news release. 

Glaukos also introduced the iDose Your Dose Initiative: for every iDose TR sold, the company pledges to make available an equal number the product for charitable donation.